INTRODUCTION

Diltiazem hydrochloride (DH) is a calcium channel blocker that relaxes vascular smooth muscle and dilates coronary arteries by altering the calcium flux into the cell.\(^1\) It has been used widely in the treatment of angina pectoris, hypertension, and cardiac arrhythmias.\(^2\) Conventional oral dosage forms of DH are intended to administer dose of 30 mg for four times a day or 60 mg thrice a day. Thus, attempts have been made to develop twice a day of oral sustained release dosage formulation for achieving better patient compliance and relative constant blood levels. It is readily absorbed from the gastrointestinal tract and undergoes substantial first-pass metabolism. The systemic bioavailability of the immediate-release preparation is approximately 40%-50%, with an elimination half-life of 3.5-7 h.\(^3\) Sustained-release DH has been reported to reduce tachycardia without inducing excessive bradycardia and does not significantly reduce baseline heart rate below 74 beats/min.\(^4\) Because of its low bioavailability and short half-life attempts have been made to develop sustained release products and a reduced dosing frequency.\(^5\)
In the last few decades, many types of peroral-modified/controlled release formulations have been developed to decrease dosing frequency and enhance patient compliance, reduce fluctuation in circular drug levels, facilitate a more uniform effect, and improve the clinical efficacy of the drug. These formulations are designed to deliver the drugs at a controlled and predetermined rate, thus maintaining their therapeutically effective concentrations in the systemic circulations for prolonged periods of time. There are a few reports on the formulation of oral-controlled release products of diltiazem employing coated beads, pan coating, microencapsulation, and complexation. But due to growing interest in the development of homogeneous monolithic drug delivery system for various routes of administration, a very attractive type of dosage form like ‘microspheres’ is required.

Microspheres are solid approximately spherical particles ranging from 1 to 100 mm in size to provide advantages over sustained release tablets such as ready distribution over a large surface area, predictable and reproducible drug release kinetics, delocalization of total dose in GIT, reduced side effects of drug, and independent drug release rate on gastric transit time. Oral multi-unit dosage forms like microspheres have received much attention as modified/controlled drug delivery systems to attribute more uniformly in the gastro-intestine tract, thus resulting more uniform drug absorption and reducing patient-to-patient variability. The multi-particulate systems can be filled into hard gelatin capsules or compressed into tablets. It has been reported that the selection of the proper microencapsulation technique and of the excipients, such as polymers as carriers, coaters, and emulsifiers, is very popular in the preparation of the modified release microspheres of the drug. In last few years, a number of studies have been made on the compression of microparticles, such as microspheres, microcapsules, and microsponges into tablets, and the effects of excipients and of the compression on the drug release rate from these formulations have been investigated. However, not a single study has been done on the filling of the matrix type microspheres of DH as compared to few studies on the tableting of the matrix type microspheres of DH.

Natural biodegradable polymeric-based microspheres as a drug carrier are widely used as they improve the safety and efficacy of drug delivery, drug targeting to specific cells or organs, and better patient compliance. Egg albumin can be used as a carrier for microsphere formulation of drugs as it has properties of protein binding and physical entrapment, the passive and facilitated release process of various types of incorporated drugs from the albumin matrix. To overcome rapid dissolution of highly soluble polymer ‘egg albumin’ in aqueous environment, different cross-linking methods have been used for microsphere preparation. Ethylcellulose, which is one of the most widely used water-insoluble polymers, in modified release dosage forms, was chosen as the matrix-forming polymer due to its good compressibility, excellent physicochemical stability, and minimum toxicity.

Hence, the purpose of the present research was to develop microspheres of DH to reduce its dosing frequency using egg albumin as a biodegradable, biocompatible carrier and an ethylcellulose as a coating polymer by the w/o emulsion thermal cross-linking method with a goal of delivering the same dose of the drug through microspheres in a capsule taken once rather than two or three times a day.

**MATERIALS AND METHODS**

**Materials**

Diltiazem hydrochloride was a gifted from Cadila Pharmaceutical Ltd., Ahmedabad, India. Egg albumin flakes and light paraffin oil of Laboratory Rasayana grade were procured from Ases laboratory, India, and Gujarat Pharmaceuticals Ltd., India, respectively. All other chemicals and solvents used were of analytical grade. The distilled water used was prepared in our laboratory.

**Methods**

**Preparation of egg albumin microspheres**

Egg albumin microspheres of DH were prepared by the w/o emulsion thermal cross-linking method with minor modification. Hundred ml of light paraffin oil was placed in a glass beaker and mixed with 0.4% w/v span 60 solution by stirring and heating at 70°C for solubilization. The mixture was allowed to cool at room temperature. Add 10 ml of egg albumin aqueous solution of a different drug to polymer ratio (1.0:1.0, 1.0:1.5 and 1.0:2.0) drop wise (various concentrations 5% w/v, 7.5% w/v, 10% w/v, and 15% w/v) to the different using a 22-gauge hypodermic syringe into an external phase. Light paraffin was stirred at 600 rpm for 10 min with the help of a magnetic stirrer (Remi equipment, 5 l capacity, Mumbai, India). A w/o emulsion was formed. The temperature of the oil bath was raised to 95°C {as preliminary study was carried out at four different temperature levels (30°C, 60°C, 80°C and at 95°C), indicating small, spherical highest percentage yielding microspheres with moderate aggregation at 95°C} and stirring was continued until microspheres were completely dehydrated. Microspheres

---

Shailesh, et al.: J Young Pharm. 2010;2(1): 27-34
Ethylcellulose microspheres of diltiazem hydrochloride were then separated by decantation and washed six times with 20 ml of petroleum ether for 2 min at 700 rpm to remove traces of oil. Finally, microspheres were washed three times with 60 zz ml of distilled water for 2 min at 700 rpm and dried at room temperature (at 25°C ± 0.5°C, 60% RH) for 24 h. After drying, a fine yellow free flowing powder was obtained that was stored in desiccators at room temperature. Different batches of microspheres were prepared using different concentrations of surfactant (span 60; 0.2% wt/vol, 0.4% wt/vol, and 0.6% w/v) and different drug to egg albumin ratios (1.0:1.0, 1.0:1.5 and 1.0:2.0). In each case, the other variables were kept constant. Average size of microspheres was determined by using a calibrated stage micrometer. A total of nine batches, each in triplicate, were prepared as per 3² factorial designs.

**Determination of percentage drug entrapment**

Efficiency of drug entrapment for each batch was calculated in terms of percentage drug entrapment (PDE) as per the formula: PDE = 100 (practical drug loading/theoretical drug loading). Theoretical drug loading was determined by calculation assuming that the entire drug present in the egg albumin solution gets entrapped in microspheres and no loss occur at any stage of preparation of microspheres. Practical drug loading was determined by crushing 100 mg of DH loaded egg albumin microspheres in a dry glass mortar containing 100 ml of distilled water. Resultant dispersion was kept aside for 3 h and 1 h in a sonicator. The dispersion was filtered through whatman filter paper (0.22 mm) and the filtrate was analyzed using a UV/Vis spectrophotometer (Hitachi U-2000) at 236.5 nm after suitable dilution with distilled water.³⁰

**Determination of mean particle size and particle size distribution**

The microspheres were characterized for size distribution by a simple optical microscope (Labomed CX RIII, India), using a calibrated stage micrometer. Geometric mean diameter (GMD) in mm was calculated using the formula: \[ X_0 = 10 \left( \frac{n \log X_i}{N} \right) \] where, \( X_i \) is the geometric mean diameter, \( n \) is the number of particles in the range, \( X_i \) is mid-point of the range, and \( N \) is the total number of microspheres (\( N = 500 \)).³¹

**In vitro drug release studies**

Release of DH from the prepared batches of microspheres were studied in distilled water (900 ml) as prescribed for diltiazem hydrochloride sustained release dosage forms in USP XXIV using apparatus I. To mimic the stomach and intestinal environments conditions, *in vitro* release study³² was also carried out for the optimized best batches of microspheres using USP dissolution rate test apparatus (Apparatus I, 100 rpm, 37 ± 0.5°C) for the first 2 h in pH 1.2 buffer (900 ml simulated gastric fluid without enzyme) and then dissolution medium was replaced with pH 7.4 phosphate buffer (900 ml) without enzyme and tested for the drug release for another 10 h.³³³⁴ A muslin cloth (200#) was tied over the basket to prevent slippage of microspheres from the basket during all dissolution studies. Microspheres equivalent to 90 mg of DH in Hard gelatin capsules (transparent, 0 size) were used for dissolution studies. 10 ml of the dissolution sample was withdrawn at different time intervals, filtered through a 0.45 mm membrane filter and replaced with an equal quantity of fresh dissolution medium. The samples were suitably diluted with dissolution fluid and analyzed for DH content spectrophotometrically at 236.5 nm. Percentage drug dissolved at different time intervals was calculated using the Beer’s-Lambert equation \( Y = 0.05125X + 0.0335, R^2 = 0.997 \). The time required for 80 % drug release (\( t_{80} \)) was calculated using Korsmeyer and Peppas model.³⁵³⁶

**Confirmation test for cross-linking**

Confirmation of thermal cross-linking of DH loaded egg albumin microspheres was done by solubility and biurate test methods.³⁷

**Optimization using factorial design**

In this investigation, the drug to polymer ratio and surfactant concentration were selected as independent variables, whereas drug loading was chosen as dependent variables. The other variables such as volume of light paraffin oil (100 ml), volume of aqueous albumin solution (10 ml of 7.5% w/v), thermal cross-linking temperature (95°C), thermal cross-linking time (60 min), and stirring speed (600 rpm) were kept constant. The formulation parameters and % yield of the factorial design batches (F1 to F9) are shown in Table 1.

**Coating to egg albumin microspheres of diltiazem hydrochloride**

To get desired sustained drug release from the microspheres, the burst effect of drug release should be reduced. Hence, egg albumin microspheres of optimized batch F2 (highest drug loading and good sphericity of microspheres) was taken for *in situ* coating using enteric polymer ethylcellulose. Coating solution of ethylcellulose of difference concentration (2.5%, 5.0% and 7.5% w/v) was prepared in acetone with dibutyl phthalate (2% v/v of polymer) as a plasticizer. It was added drop wise to the dispersion containing DH-loaded egg albumin microspheres. The system was stirred for 30 min, filtered (0.45 m size filter medium), washed six times with 6 ml volumes of petroleum ether, and dried at room temperature (25°C ± 0.5°C, 60% RH) for 24 h. A total of three batches,
Table 1: A 3² full factorial design layout

| Batch code | Variable levels in coded forms | Y₉₀ (%) | Y₃60 (%) | t₈₀ | t₃60 | Drug entrapment efficiency (%) | GMD ± SD (μm) |
|------------|-------------------------------|---------|----------|-----|------|------------------------------|----------------|
| F1         | -1                            | 55.17   | 78.42    | 367 | 54   | 61.76                        | 52.13 ± 1.1    |
| F2         | -1                            | 57.00   | 78.08    | 369 | 53   | 79.2                         | 47.30 ± 1.5    |
| F3         | -1                            | 56.22   | 78.73    | 366 | 53   | 65                           | 46.50 ± 2.1    |
| F4         | 0                             | 51.65   | 79.16    | 363 | 58   | 59.5                         | 61.40 ± 2.6    |
| F5         | 0                             | 50.45   | 77.29    | 37  | 360  | 62.25                        | 47.50 ± 1.9    |
| F6         | 0                             | 50.38   | 78.13    | 369 | 60   | 52.5                         | 47.10 ± 3.1    |
| F7         | 1                             | 48.96   | 76.01    | 379 | 61   | 55.5                         | 74.41 ± 2.5    |
| F8         | 1                             | 48.23   | 76.81    | 375 | 62   | 58.25                        | 66.63 ± 2.8    |
| F9         | 1                             | 47.14   | 75.42    | 382 | 64   | 48                           | 59.65 ± 1.6    |

Translation of coded levels in actual units

| Variable level | Low (−1) | High (+1) |
|----------------|----------|-----------|
| Drug to polymer ratio (X₁) | 1.0:1.0 | 1.0:2.0 |
| Surfactant concentration (X₂) | 0.2 | 0.6 |

Y₉₀, Y₃60 = the percentage drug released in 60 min and 360 min, t₈₀, t₃60 = the time in minutes required for 80% drug dissolution All the batches were prepared using 10 ml 7.5% w/v egg albumin solution, 95°C cross linking temperature, 100 ml light paraffin oil and 60 minutes cross linking time.

each in triplicates, were prepared to optimize the percentage ethylcellulose coating on batch F2 microspheres.

Stability studies

To assess long-term stability, the ethylcellulose-coated egg albumin microsphere formulations in triplicate (batch C3 of 7.5% w/v ethylcellulose coating) were put in hard gelatin capsules (transparent, 0 size) and sealed in aluminum packaging coated inside with polyethylene. The studies were performed at 40°C/75% RH in the stability chamber (Stability Oven, Nirmal Instruments, Delhi, India) for 3 months. At the end of storage period, the formulation was observed for physical appearance, size, shape, surface morphology, drug content, and in vitro drug release studies.

Comparison of in vitro drug release of optimized egg albumin microsphere, batch C₃, to C₁ and market formulation

In vitro dissolution study in triplicate was carried out for the coated microsphere batches (C₁, C₂ and C₃) and uncoated DH-loaded egg albumin microspheres, using the same method as described earlier in comparison to market formulation of DH microspheres (90 mg Angezem® CD; Capsule: Aztecz: Sun Pharmaceutical Research center, Baroda, Gujarat, India).

RESULTS AND DISCUSSION

Preliminary trials

The presence of 0.4% w/v span 60 (HLB 5-6) was found to be essential to minimize aggregation of egg albumin droplets during the emulsification step and effective to achieve spherical, small, regular, discrete microspheres with good yield. The type and quality of the oil phase played an important role in controlling the diameter of microspheres. Two types of liquid paraffin (light or heavy) and cottonseed oil were tried. When cottonseed oil and heavy liquid paraffin were used, greater resistance was offered in the process of dispersion, leading to the formation of aggregated irregular-shaped microspheres compared to that of light liquid paraffin. Thus, light liquid paraffin oil was selected and effect of its volume (75, 100, and 150 ml) on the characteristics of microspheres was studied. Discrete, small, regular, and spherical microspheres were obtained when 100 ml of light paraffin oil was used. To study the effect of stirring speed, microspheres were prepared at 100, 250, and 600 rpm. Microspheres with good sphericity were obtained at 600 rpm.

The geometric mean diameter of egg albumin microspheres varied from 47.30 ± 1.5 μm to 59.65 ± 1.6 μm with varying egg albumin concentration. The average percentage drug entrapment was found to be 69.6 ± 4% in all the microsphere formulations. The highest drug loading efficiency was found with 7.5% w/v egg albumin. Three different ratios of drug to egg albumin (1.0:1.0, 1.0:1.5 and 1.0:2.0 wt/wt) were tried. Microspheres prepared using the 1.0:1.0 wt/wt drug to egg albumin ratio showed highest t₈₀ (389 min), % drug entrapment efficiency (79.20%), and small (GMD: 47.50 ± 1.5), spherical, discrete microspheres. A higher concentration of egg albumin produced a more viscous dispersion, which formed larger droplets and consequently larger microspheres as reported by Pongpaibul et al.[39] However, the microspheres showed a burst effect (55% drug release in 1 h) and a relatively faster drug release thereafter (total drug release in 6 hour). In situ coating of microspheres with ethylcellulose significantly reduced the burst effect (5% drug release in 1 h).
Effect of emulsifier concentration on characteristics of microspheres

The geometric mean diameter of microspheres was found to vary from 52.13 ± 1.1 μm to 46.50 ± 2.1 μm on varying emulsifier (Span 60) concentration. Increased surfactant concentration led to the formation of microspheres with a lower GMD as reported by Chemtob et al. Increasing Span 60 concentration from 0.2% to 0.6% wt/vol led to stabilization of the emulsion droplets avoiding their coalescence, resulting in smaller microspheres. The drug loading efficiency varied from 60.70 ± 0.9% to 78.13 ± 1.3% with varying emulsifier concentration from 0.2% to 0.6% during preparation of egg albumin microspheres.

The GMD of egg albumin microspheres decreased from 61.71 ± 2.0 μm to 47.30 ± 1.5 μm with increasing speed of the magnetic stirrer from 100 rpm to 600 rpm. This result was expected because high stirring rates provide the shearing force needed to separate the oil phase into smaller globules. The stirring speed of 600 rpm was found to be optimum for egg albumin microspheres, as the drug loading efficiency was 78.21 ± 1.6% at this speed. High stirring speed produced an irregular shape of microspheres, but an increased drug entrapment efficacy was found. Stirring time of 60 min was found to be optimum for egg albumin microspheres because at this time period, the microsphere size was small with good drug loading efficiency of 70.25 ± 1.2%.

Effect of cross-linking temperature and time on microspheres

An increase in cross-linking temperature from 60°C to 95°C leads to a decrease in GMD. This is due to increase in the degree of congealing or rigidization of egg albumin that ultimately results in shrinking of the particles irrespective of the cross-linking time. Increase cross-linking time from 60 min to 120 min irrespective to cross-linking temperature did not show any significant change in GMD. At 95°C cross-linking temperature, cross-linking time of 60 min was enough for conversion of water from liquid state to vapor and hence complete removal of water present in the dispersed phase. This process starts essentially when the time of cross-linking is nearly 50 min, indicating no need to increase cross-linking temperature to get discrete spherical small with high percentage drug loading microspheres. Further increase in cross-linking time at the same temperature did not give the desired product characteristics but showed a step fall in the drug entrapment efficiency; it may be due to the loss of the drug present on the surface of the microspheres to the dispersion medium. It is surface-bound drug that is loosely held and usually lost to the externally oily phase during preparation or to solvents during the washing stage. Increase in cross-linking time at constant cross-linking temperature did not have a significant effect on the % drug loading.

Full factorial design

The results depicted in Table 1 clearly indicate that the selected dependent variables are strongly dependent on the selected independent variables as they show a wide variation among the nine batches (F1 to F9). The main effects ($X_1$ and $X_2$) represent the average result of changing one factor at a time from its low to high value. The interactions ($X_1X_2$) show how the response value changes when the two factors are simultaneously changed. The polynomial terms ($X_1X_2$ and $X_1^2$) were included in the model to investigate non-linearity. The fitted equations (full models) relating the response, i.e. the %drug loading efficiency, to the transformed factor are shown in Table 1. The polynomial equations can be used to draw conclusions after considering the magnitude of coefficient and the mathematical sign it carries, i.e. positive or negative. The high value of correlation coefficient [Table 1] for the dependent variable indicates a good fit. The equation may be used to obtain estimates of the response since small error of variance was noticed in the replicates.

The polynomial equations relating the responses $Y_{60}$ and $t_{80}$ to the transferred factors are:

$$Y_{60} = 51.0311 - 4.01X_1 - 0.34X_2 - 0.9175X_1X_2 + 1.2933X_1X_1 - 0.3067X_2X_2$$

$$t_{80} = 369.22 + 5.66X_1 + 1.3333X_2 + 1.00X_1X_2 + 4.667X_1X_1 - 1.3333X_2X_2$$

The response values for the nine batches showed a wide variation; $Y_{60}$ ranged from 47.14 to 57.00% and $t_{80}$ ranged from 291 to 395 min. The data clearly indicate that $Y_{60}$ and $t_{80}$ values depend significantly on the selected independent variables. The high value of correlation coefficient ($r = 0.9930$ for $Y_{60}$ and $r = 0.9970$ for $t_{80}$) indicates a good fit. The equation (2) represents that the coefficients associated with $X_1$ carry a negative sign. The $Y_{60}$ was found to be inversely related to the polymer to drug ratio. Figures 1-4 show the response surface plots drawn using Sigma Plot software (Jandel Scientific Software, San Rafael, CA).
Kinetic modeling of drug release

The method of Bamba et al. was adopted to decide the most appropriate model. For the optimize batch (Batch F2), the release profile fitted to the Korsmeyer and Peppas model ($F = 4.41$) giving the least residual sum of squares as compared to the Weibull model ($F = 6.03$) and Higuchi model ($F = 98.83$). This superiority is, however, statistically insignificant as shown by the F-ratio test. For the batch F2, the values of correlation coefficient were found to be 0.97, 0.97, and 0.94 for Korsmeyer and Peppas, Weibull, and Higuchi models, respectively. Out of nine batches, the Korsmeyer and Peppas model fitted well to all batches except one. Thus, the Korsmeyer and Peppas model was selected. For the Korsmeyer and Peppas model, the values of slope and intercept were found to be 0.5219 and $-0.7548$, respectively. From the value of slope ($n = 0.5219, 0.45 < n < 0.89$), it can be concluded that the drug is released by diffusion of anomalous type (non-Fickian).

Selection of best batch

An ideal modified formulation is one from which a loading dose ($<30\%$) is released in the first hour and the remaining $70\%$ of the drug is released thereafter at a constant rate ($6.36\%$ per hour). The following constraints were chosen for the selection of the best batch; $Y_{50} < 30\%$, $52\% < Y_{300} < 62\%$ and $70\% < Y_{480} < 80\%$. Not a single batch from F1 to F9 met all the three selection criteria. But for microspheres, drug content is an important parameter because it determines the quantity of microspheres required to deliver the dose of a drug. The microspheres of batch F2 exhibited higher drug entrapment efficiency ($79.20\%$ w/v). The microspheres showed small, discrete, good spherical geometry as shown in Figures 5 and 6. To lower the loading dose and obtain desired release profile, batch F2 microspheres were coated with enteric polymer ethylcellulose. Batch C3 microspheres showed the desired in vitro release profile compared to that of batch C1, C2,
Ethylcellulose microspheres of diltiazem hydrochloride

It means that the batch C3 product mimic the release profile of DH of market formulation.

Stability studies

Stability studies revealed that polymers used were stable and compatible with the drug and no significant difference were found in physical appearance, particle size and shape, drug content, and in vitro drug release during stability study, and similarity factor $f_2$ and dissimilarity factor $f_1$ were found to be 0.96 and 0.15, respectively.

CONCLUSION

From the present investigation it was concluded that ethylcellulose-coated egg albumin microsphere, can be considered as an effectively coated carrier for the design of a controlled drug delivery system of highly water-soluble DH.

ACKNOWLEDGEMENTS

Authors thank Cadila Pharmaceuticals Limited, Ahmedabad, India, for a gift sample of Diltiazem HCL. Authors also thank Dr. M. C. Gohel, Principal, L. M. College of Pharmacy, Ahmedabad, for extending required laboratory facilities for the present work.

REFERENCES

1. Schwartz A, Grupp G, Millard RW. Calcium channel blocks: Possible mechanism of protective effects on the ischemic myocardium. In: Weiss GB (ed.), New Perspectives on Calcium Antagonists. Bethesda, MD: American Physiological Society; 1981. p. 191-210.
2. Buckley MM, Grant SM, Goa KL, McTavish D, Sorkin EM. Diltiazem—a reappraisal of its pharmacological properties and therapeutic use. Drugs 1990;39:757-806.
3. Eichizen H, Eichelbaum M. Clinical pharmacokinetics of verapamil, nifedipine and diltiazem. Clin Pharmacokinet 1986;11:425-9.
4. Boden WE, Vray M, Eichelbaum M, Lauret D, Scheldewaert R. Heart rate-lowering and regulating effects of once-daily sustained-release diltiazem. Clin Cardiol 2001;24:73-9.
5. Murata K, Yamahara H, Kobayashi M, Noda K, Samejima M. Pharmacokinetics of an oral sustained release diltiazem preparation. J Pharm Sci 1989;78:960-3.
6. Robinson JR, Li VH, Lee VH. Influence of drug properties and routes of drug administration on the design of sustained and controlled release systems. In: Robinson JR, Lee VH, editors. Controlled drug delivery fundamentals and applications, 2nd ed., New York: Marcel Dekker Inc; 1987. p. 4-94.
7. Sood A, Pachagnula R. Drug release evaluation of diltiazem CR preparations. Int J Pharm 1998;175:95-107.
8. Debseck AM, Baudier PR. Extended release form of diltiazem, WO/1993/000093. Pet: Ca1992/000290.
9. Vaneckova K, DjuricZ, Jovanovic M, Simov A. Preparation and dissolution characteristics of controlled release diltiazem pellets. Drug Dev Ind Pharm 1992;18:1649-61.
10. Chowdary KP, Ramesh KV. Studies on Microencapsulation of Diltiazem. Indian J Pharm Sci 1993;55:52-4.
11. Horiuchi Y, Hiyama F, Uekama K. Slow release characteristics of diltiazem from ethylated beta-cyclodextrin complexes. J Pharm Sci 1990;79:128-32.
12. Swarbrick J, Boylan JC. Encyclopaedia of Pharm. Technology: Vol. 10, Marcel Dekker, Inc: New York; 1990. p. 55 and 199.
13. Silber BM, Bialer M and Yacobi A. Controlled Drug Delivery. Fundamentals and Application: Vol. 29, 2nd Edi. Robinson JR, Lee, Marcel Dekker Inc: New York; 1987. p. 217.
14. Celik M. Compaction of multiparticulate oral dosage forms. In: Ghebre-Sellassie I, editor. Multiparticulate oral drug delivery. New York; Marcel Dekker Inc; 1994. p. 181-215.

15. Bhalerao SS, Lalla JK, Rane MS. Study of processing influencing the properties of diltiazem hydrochloride microspheres. J Microencapsul 2001;18:299-307.

16. Kim CK, Kim MJ, Oh KH. Preparation and evaluation of sustained release microspheres of terbutaline sulfate. Int J Pharm 1995;106:213-9.

17. Soppimuth KS, Kalkarni AR, Aminabhavi TM. Evaluation of antihypertensive drugs in cellulose-based matrix microspheres: Characterization and release kinetics of microspheres and tableted microspheres. J Microencapsul 2001;18:397-409.

18. Das SK, Das NG. Preparation and in-vitro dissolution profile of dual polymer (Edracti® RS 100 and RL100) microparticles of diltiazem hydrochloride. J Microencapsul 1998;15:445-52.

19. Kristmundsdottir T, Ingvarsdottr K. Influence of emulsifying agents on the properties of cellulose acetate butyrate and ethylcellulose microcapsules. J Microencapsul 1994;11:633-9.

20. Kakish HF, Tashoob B, Ibrahim HG, Najib NM. A novel approach for the preparation of highly loaded polymeric controlled release dosage forms of diltiazem HCl and diclofenac sodium. Eur J Pharm Biopharm 2002;54:75-81.

21. Bayomi MA, al-Suwayeh SA, el-Helw AM, Mesnad AF. Preparation of highly loaded polymeric controlled release dosage forms of diltiazem hydrochloride. Int J Pharm 1993;92:29-34.

22. Sengel CT, Hasçiçek C, Gönül N. Development and in-vitro evaluation of modified release tablets including ethylcellulose microspheres loaded with diltiazem hydrochloride. J Microencapsul 2006;23:135-52.

23. Dussey RR, Parikh JR, Parikh RR. Effect of heating temperature and time on Pharmaceutical characteristics of albumin Microspheres containing 5-Fluorouracil. AAPS PharmSciTech 2003;4:E4.

24. Gupta PK, Hung CT, Lam FC, Perrier DG. Albumin microspheres, III: Synthesis and characterization of microspheres containing Adriamycin and magnetic. Int J Pharm 1988;43:167-77.

25. Dhavan A, Vyas SP, Jain NK, Varma KC. In vitro evaluation of albumin microspheres containing actinomycin, Drug Dev Ind Pharm 1991;17:2229-37.

26. Illum L, Davis SS. Polymers in controlled drug delivery systems, IOP publishing Ltd., Bristol, 1987.

27. Shailesh, et al.: J Young Pharm. 2010;2(1): 27-34